OpenScience.ink

2 weeks ago • Cureus

Starting Glucagon-Like Peptide-1 Therapy and Lifestyle Changes for Severe Obesity in a Patient with Irregular Heartbeats, Joint Pain, and Sleep ApneaInitiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Lifestyle Modifications for Morbid Obesity in a Patient With Paroxysmal Atrial Fibrillation, Severe Osteoarthritis, and Obstructive Sleep Apnea: A Case Report.

Case Reports

3 weeks ago • AME case reports

Severe iron deficiency anemia despite iron treatment linked to semaglutide use: a case reportWhere did the iron go?-a case report of a patient with severe iron deficiency anemia despite parenteral and oral iron supplementation due to semaglutide application.

Case Reports

2 days ago • Bone

Glucagon-like peptide-1 receptor agonists and their impact on bone metabolism: A review and analysis of controlled trials with mainly first-generation drugsThe effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents.

Article

3 days ago • Current problems in cardiology

Link between diabetes medicines and outcomes after pacemaker surgery in type 2 diabetes patientsAssociation of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.

Article

3 days ago • Cureus

Skin Reactions Linked to Semaglutide: A Review and Combined Analysis of Clinical TrialsCutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Article

4 days ago • Cureus

Protecting Muscle Health During Weight Loss with Lifestyle, Surgery, and MedicationPreserving Muscle Health During Weight Loss: Evidence Across Lifestyle, Surgical, and Pharmacological Interventions.

Article

5 days ago • Journal of psychiatric research

Current clinical trials of incretin-based treatments for mental health conditionsIncretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov.

Article

5 days ago • JAMA

Are GLP-1 Drugs Safe for People Who Are Frail?Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?

Article

5 days ago • Saudi journal of anaesthesia

Stomach contents in obese patients taking GLP-1 drugs measured by ultrasoundGastric residual volume in patients with obesity receiving GLP-1 receptor agonists: A comparative gastric ultrasound pilot study.

Article

5 days ago • Saudi journal of anaesthesia

Guidelines for Managing Diabetes Drugs During Surgery for AnesthesiologistsPerioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.

Article

5 days ago • Saudi journal of anaesthesia

Managing patients on GLP-1 receptor drugs around surgery: Comparing international guidelinesPerioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.

Article

6 days ago • Journal of the American Geriatrics Society

Safe and Personalized Use of Weight Loss Medicines in Older Adults Using the Geriatrics 5Ms ApproachObesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.

Article

6 days ago • Cureus

Effects of Glucagon-Like Peptide-1 Drugs on Reproduction and Women's Health in Polycystic Ovary SyndromeReproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review.

Article

6 days ago • Diabetes, obesity & metabolism

Early use patterns and long-term continuation of semaglutide for obesity in a large populationEarly Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study.

Article

1 week ago • Diabetes care

A Controlled Study of Acmopatide, a Targeted Hormone Drug, in Overweight Adults with Type 1 DiabetesA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.

Article

1 week ago • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

A clinical approach to multiorgan incretin therapy based on receptor structure and treatment stageFrom receptor architecture to outcome maturity: a clinical framework for multiorgan incretin therapy.

Article

1 week ago • Diabetes, obesity & metabolism

Tirzepatide led to significant weight loss over 12 months in people with obesity or overweightTirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results.

Article

1 week ago • Diabetes, obesity & metabolism

Article

1 week ago • Health affairs scholar

Prescription denials for diabetes and weight-loss drugs under commercial, Medicare, and Medicaid plans from 2018 to 2024Prescription denials for GLP-1 receptor agonists across commercial, Medicare, and Medicaid coverage, 2018-2024.

Article

1 week ago • Diabetes care

Comparing Semaglutide, Dulaglutide, and Liraglutide in Patients on Kidney DialysisTarget Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.

Article

1 week ago • Transplantation

Effects of Glucagon-like Peptide-1 Drugs in Heart Transplant Patients with Type 2 DiabetesGlucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.

Article

1 week ago • Drug discovery today

How matching drug targets, types, and forms explains treatments using hormone and nutrient sensors for type 2 diabetesIncretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target-modality-formulation matching explains.

Article

1 week ago • Cureus

IcoSema's role in weight loss and blood sugar control: A review and analysisIcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis.

Article

1 week ago • Diabetes, obesity & metabolism

Brain and mental health outcomes linked to diabetes drug use in Medicare patients with type 2 diabetes, varying by treatment type and obesityNeuropsychiatric Outcomes Associated With GLP-1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status.

Article

1 week ago • Cureus

Surgery Safety and Results Linked to GLP-1-Based TreatmentsPerioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review.

Article

1 week ago • Life sciences

Lack of GHSR gene and LEAP2 treatment increase liraglutide’s blood sugar lowering effects in male mice depending on their metabolic stateGenetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.

Article

1 week ago • European journal of obstetrics, gynecology, and reproductive biology

How common and changing use of weight-loss drugs is before and during pregnancy in the US from 2018 to 2023Prevalence and temporal trends of exposure to anti-obesity medications during preconception and pregnancy in a nationwide US claims database, 2018-2023.

Article

1 week ago • Diabetes, obesity & metabolism

Changes in Other Medication Use After Starting SemaglutideImpact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series.

Article

1 week ago • Cureus

Tirzepatide's effects on insulin-producing cell function in adults with type 2 diabetesEffects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review.

Article

1 week ago • Cureus

Body Weight and Fat Changes with Standard versus Low Dose Tirzepatide in Women with LipedemaBody Composition Changes With Standard Versus Low-Dose Tirzepatide Titration in Women With Lipedema: A Retrospective Observational Study.

Article

← prevpage 14 of 16next →

GLP-1 Therapies Research Papers